Cargando…

The combination of MnO(2)@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer

It can be found from a large number of cancer treatments that use of anti-cancer drugs alone often presents low efficacy and high side effects. This study aims to develop a new drug carrier with tumor-specific response, controlled release in vivo and high tumor-suppressive property. Inorganic nano-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jisong, Xu, Li, Hu, Huihui, Chen, Enguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843201/
https://www.ncbi.nlm.nih.gov/pubmed/35147070
http://dx.doi.org/10.1080/10717544.2022.2032872